| CRISPR-Cas9 gene therapy for Duchenne muscular dystrophy CH Mbakam, G Lamothe, G Tremblay, JP Tremblay Neurotherapeutics 19 (3), 931-941, 2022 | 32 | 2022 |
| Therapeutic strategies for dystrophin replacement in Duchenne muscular dystrophy C Happi Mbakam, G Lamothe, JP Tremblay Frontiers in Medicine 9, 859930, 2022 | 29 | 2022 |
| Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro A Guyon, J Rousseau, FG Bégin, T Bertin, G Lamothe, JP Tremblay Molecular Therapy-Nucleic Acids 24, 253-263, 2021 | 26 | 2021 |
| The protective mutation A673T in amyloid precursor protein gene decreases Aβ peptides production for 14 forms of Familial Alzheimer’s Disease in SH-SY5Y cells A Guyon, J Rousseau, G Lamothe, JP Tremblay PLoS One 15 (12), e0237122, 2020 | 14 | 2020 |
| CRISPR/Cas9 delivery strategies with engineered extracellular vesicles Y Lu, K Godbout, G Lamothe, JP Tremblay Molecular Therapy-Nucleic Acids, 2023 | 4 | 2023 |
| Prime editing strategies to mediate exon skipping in DMD gene C Happi Mbakam, J Roustant, J Rousseau, P Yameogo, Y Lu, A Bigot, ... Frontiers in Medicine 10, 1128557, 2023 | 2 | 2023 |
| Base editing strategy allows insertion of the A673T mutation in APP gene to prevent the development of Alzheimer’s disease A Guyon, J Rousseau, FG Bégin, T Bertin, G Lamothe, JP Tremblay bioRxiv, 2020.10. 27.357830, 2020 | 1 | 2020 |
| Protective mutation A673T as a potential gene therapy for most forms of APP Familial Alzheimer’s Disease A Guyon, J Rousseau, G Lamothe, JP Tremblay bioRxiv, 2020.07. 22.215616, 2020 | 1 | 2020 |
| Rapid and Technically Simple Detection of SARS-CoV-2 Variants Using CRISPR Cas12 and Cas13 G Lamothe, J Carbonneau, C Joly Beauparlant, T Vincent, P Quessy, ... The CRISPR Journal 6 (4), 369-385, 2023 | | 2023 |
| Insertion of the protective APP A673T mutation by CRISPR/Cas9 base editing or PRIME editing. J Tremblay, A Guyon, J Rousseau, G Tremblay, FG Begin, G Lamothe Innovation in Aging 5 (Suppl 1), 665, 2021 | | 2021 |
| Detection of SARS-CoV-2 Using LAMP and CRISPR/Cas13a G Lamothe, J Tremblay Molecular Therapy, 426-427, 2021 | | 2021 |
| Development of a new therapeutic approach for familial and sporadic Alzheimer diseases: insertion of the Icelandic protective mutation by CRISPR/Cas9 PRIME editing. JP Tremblay, A Guyon, G Tremblay, J Rousseau, GP Lamothe, ... 2021 Alzheimer's Association International Conference, 0 | | |
